Sage Journals: Discover world-class research

Abstract

Background

Oxidized low-density lipoprotein (ox-LDL) contributes to atherosclerosis and triggers cardiovascular and cerebrovascular events. However, its role in cognitive impairment (CogI) has not been fully elucidated.

Objective

To examine the relationship between plasma ox-LDL and all-cause CogI in middle-aged and older Chinese adults.

Methods

In this population-based cross-sectional study using cluster sampling, cognitive function was assessed with the Mini-Mental State Examination (MMSE) and neuropsychological tests. CogI was diagnosed based on criteria for mild cognitive impairment (MCI) and dementia. Plasma ox-LDL was measured by ELISA and analyzed as restricted cubic spline (RCS), continuous, and binary variables. Logistic regression, subgroup, and interaction analyses were performed.

Results

Among 1406 subjects, 112 (8.0%) had CogI. RCS analysis showed a significant association between ox-LDL and CogI (p_overall < 0.001), with no non-linear relationship (p_non−linear = 0.327). Individuals with ox-LDL >1002.88 ng/mL had a higher risk of CogI than those with ox-LDL ≤1002.88 ng/mL (10.7% versus 6.6%, p = 0.008; OR = 1.749, 95% CI: 1.134–2.697, p = 0.012). The association remained significant among participants with normal TC (TC < 5.18 mmol/L, p < 0.001), but was not observed in those with elevated TC (p = 0.817). Interaction analysis confirmed a modifying effect of TC (p_interaction = 0.005), and a similar effect was observed for LDL-C (p_interaction = 0.028).

Conclusions

Elevated ox-LDL levels (>1002.88 ng/mL) were associated with an increased risk of all-cause CogI, particularly among individuals with normal TC or LDL-C. Longitudinal studies with larger sample sizes are needed to clarify the causal relationship.

Keywords

Alzheimer's disease cognitive impairment cross-sectional study oxidized low-density lipoprotein risk factor

Get full access to this article

View all access options for this article.

References

Patterson

. World Alzheimer Report 2018. The state of the art of dementia research: New frontiers. London: Alzheimer's Disease International, 2018.

GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022; 7: e105–e125.

Alzheimer's Association. 2024 Alzheimer's disease facts and figures. Alzheimers Dement 2024; 20: 3708–3821.

Livingston

Huntley

Liu

, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 2024; 404: 572–628.

Parthasarathy

Raghavamenon

Garelnabi

, et al. Oxidized low-density lipoprotein. Methods Mol Biol 2010; 610: 403–417.

Allen

Bayraktutan

. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009; 4: 461–470.

Guldiken

Turgut

, et al. The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke. Angiology 2008; 59: 224–229.

Dias

Mistry

Fell

, et al. Oxidized LDL lipids increase β-amyloid production by SH-SY5Y cells through glutathione depletion and lipid raft formation. Free Radic Biol Med 2014; 75: 48–59.

Grochowski

Litak

Kamieniak

, et al. Oxidative stress in cerebral small vessel disease. Role of reactive species. Free Radic Res 2018; 52: 1–13.

10.

Lin

Chang

Chen

, et al. Resveratrol protects against oxidized LDL-induced breakage of the blood-brain barrier by lessening disruption of tight junctions and apoptotic insults to mouse cerebrovascular endothelial cells. J Nutr 2010; 140: 2187–2192.

11.

Ahmadi

Panahi

Johnston

, et al. Antidiabetic drugs and oxidized low-density lipoprotein: a review of anti-atherosclerotic mechanisms. Pharmacol Res 2021; 172: 105819.

12.

Murr

Carmichael

Julien

, et al. Plasma oxidized low-density lipoprotein levels and risk of Alzheimer's disease. Neurobiol Aging 2014; 35: 1833–1838.

13.

Koyama

Stone

Yaffe

. Serum oxidized low-density lipoprotein level and risk of cognitive impairment in older women. Neurobiol Aging 2013; 34: 634–635.e2.

14.

Bacchetti

Vignini

Giulietti

, et al. Higher levels of oxidized low density lipoproteins in Alzheimer's disease patients: roles for platelet activating factor acetyl hydrolase and paraoxonase-1. J Alzheimers Dis 2015; 46: 179–186.

15.

Zhao

Zhou

Peng

, et al. Expression and significance of plasma 3-NT and ox-LDL in patients with Alzheimer's disease. Genet Mol Res 2014; 13: 8428–8435.

16.

Siri

Krauss

. Influence of dietary carbohydrate and fat on LDL and HDL particle distributions. Curr Atheroscler Rep 2005; 7: 455–459.

17.

Wang

Gao

Liu

, et al. The association of plasma amyloid-beta and cognitive decline in cognitively unimpaired population. Clin Interv Aging 2022; 17: 555–565.

18.

Katzman

Zhang

Ouang Ya

, et al. A Chinese version of the mini-mental state examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol 1988; 41: 971–978.

19.

Fuld

Masur

Blau

, et al. Object-memory evaluation for prospective detection of dementia in normal functioning elderly: predictive and normative data. J Clin Exp Neuropsychol 1990; 12: 520–528.

20.

Henry

Crawford

Phillips

. Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis. Neuropsychologia 2004; 42: 1212–1222.

21.

Johanson

Gustafson

Risberg

. Behavioral observations during performance of the WAIS block design test related to abnormalities of regional cerebral blood flow in organic dementia. J Clin Exp Neuropsychol 1986; 8: 201–209.

22.

Simard

van Reekum

. Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease. Drugs Aging 1999; 14: 197–230.

23.

Bowie

Harvey

. Administration and interpretation of the trail making test. Nat Protoc 2006; 1: 2277–2281.

24.

Mlinac

Feng

. Assessment of activities of daily living, self-care, and independence. Arch Clin Neuropsychol 2016; 31: 506–516.

25.

Sharp

. The Hamilton rating scale for depression. Occup Med 2015; 65: 340–340.

26.

Moroney

Bagiella

Desmond

, et al. Meta-analysis of the hachinski ischemic score in pathologically verified dementias. Neurology 1997; 49: 1096–1105.

27.

Petersen

. Clinical practice. Mild cognitive impairment. N Engl J Med 2011; 364: 2227–2234.

28.

McKhann

Drachman

Folstein

, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939–944.

29.

Gao

Wei

Dang

, et al. Sleep disturbance is associated with mild cognitive impairment: a community population-based cross-sectional study. BMC Public Health 2022; 22: 2000.

30.

Chatterjee

Khunti

Davies

. Type 2 diabetes. Lancet 2017; 389: 2239–2251.

31.

James

Oparil

Carter

, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA 2014; 311: 507–520.

32.

Zhou

. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults–study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 2002; 15: 83–96.

33.

Kassner

Bonaterra

Kaiser

, et al. Novel systemic markers for patients with Alzheimer disease? - a pilot study. Curr Alzheimer Res 2008; 5: 358–366.

34.

Farrer

Cupples

Haines

, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 1997; 278: 1349–1356.

35.

Krishnamurthy

Rajavelu

Reddy

, et al. Association of apolipoprotein E (APOE) polymorphisms with serological lipid and inflammatory markers. Cureus 2024; 16: e60721.

36.

Arce Rentería

McClure

Callas

, et al. Lipoprotein(a) and risk of cognitive impairment in black and white Americans: the reasons for geographic and racial differences in stroke cohort. Res Pract Thromb Haemost 2023; 7: 102170.

37.

Agarwal

Morris

Barnes

. Racial differences in dietary relations to cognitive decline and Alzheimer's disease risk: do we know enough? Front Hum Neurosci 2020; 14: 359.

38.

Miller

3rd Appel

Risby

. Effect of dietary patterns on measures of lipid peroxidation: results from a randomized clinical trial. Circulation 1998; 98: 2390–2395.

39.

Kapasi

DeCarli

Schneider

. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol 2017; 134: 171–186.

40.

Kawas

Kim

Sonnen

, et al. Multiple pathologies are common and related to dementia in the oldest-old: the 90+ study. Neurology 2015; 85: 535–542.

41.

Schneider

Arvanitakis

Bang

, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197–2204.

42.

Jiang

Zhou

Nabavi

, et al. Mechanisms of oxidized LDL-mediated endothelial dysfunction and its consequences for the development of atherosclerosis. Front Cardiovasc Med 2022; 9: 925923.

43.

Wang

Yang

, et al. Association of oxidized low-density lipoprotein with prognosis of stroke and stroke subtypes. Stroke 2017; 48: 91–97.

44.

Wang

Liu

Meng

, et al. Association between oxidized low-density lipoprotein and cognitive impairment in patients with ischemic stroke. Eur J Neurol 2018; 25: 185–191.

45.

Keller

Hanni

Markesbery

. Oxidized low-density lipoprotein induces neuronal death: implications for calcium, reactive oxygen species, and caspases. J Neurochem 1999; 72: 2601–2609.

46.

Parthasarathy

Young

Witztum

, et al. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986; 77: 641–644.

47.

Bird

Tangirala

Fruebis

, et al. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J Lipid Res 1998; 39: 1079–1090.

48.

Dang

Wei

Zhao

, et al. Effects of probucol on plasma amyloid-β transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial. Lipids Health Dis 2024; 23: 410.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.74 MB

The relationship between plasma oxidized low-density lipoprotein and all-cause cognitive impairment: A population-based cross-sectional study in a rural area of Xi’an,China

Abstract

Background

Objective

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material